OBJECTIVES: Resveratrol (RV), a natural polyphenol derived from red wine, recently showed the potential of anticancer and radiosensitizing effects. A recent study has suggested that the cancer stem cells (CSCs) may reflect the clinical refractory malignancy of brain tumors, including medulloblastoma (MB). The aim of the present study is to investigate the possible role of RV in radiosensitivity of MB cells and MB-associated CSCs. MATERIALS AND METHODS: MB-associated CSCs were isolated and cultured by serum-free medium with basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). The parental MB cells and MB-CSCs were treated with RV in different concentrations and assessed for cell viability. The treatment includes RV alone, radiation alone, or radiation combined with RV. RESULTS: MB-CSCs selected by serum-free medium with bFGF and EGF can form 3D spheroid formation and display enhanced self-renewal and highly co-expressed "stem cell" genes (Oct-4, Nanog, Nestin, and Musashi-1) as well as antiapoptotic genes (Bcl-2 and Bcl-xL). These MB-CSCs showed significant resistance to radiotherapy as compared to the parental MB cells. Importantly, 100 muM RV could effectively inhibit the proliferation of MB-CSCs and significantly enhance the radiosensitivity in RV-treated MB-CSCs. CONCLUSIONS: Our data suggest that RV can effectively inhibit the proliferation and tumorigenicity of MB-CSCs and significantly synergistically enhance radiosensitivity in RV-treated MB-CSCs.
OBJECTIVES:Resveratrol (RV), a natural polyphenol derived from red wine, recently showed the potential of anticancer and radiosensitizing effects. A recent study has suggested that the cancer stem cells (CSCs) may reflect the clinical refractory malignancy of brain tumors, including medulloblastoma (MB). The aim of the present study is to investigate the possible role of RV in radiosensitivity of MB cells and MB-associated CSCs. MATERIALS AND METHODS: MB-associated CSCs were isolated and cultured by serum-free medium with basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). The parental MB cells and MB-CSCs were treated with RV in different concentrations and assessed for cell viability. The treatment includes RV alone, radiation alone, or radiation combined with RV. RESULTS: MB-CSCs selected by serum-free medium with bFGF and EGF can form 3D spheroid formation and display enhanced self-renewal and highly co-expressed "stem cell" genes (Oct-4, Nanog, Nestin, and Musashi-1) as well as antiapoptotic genes (Bcl-2 and Bcl-xL). These MB-CSCs showed significant resistance to radiotherapy as compared to the parental MB cells. Importantly, 100 muM RV could effectively inhibit the proliferation of MB-CSCs and significantly enhance the radiosensitivity in RV-treated MB-CSCs. CONCLUSIONS: Our data suggest that RV can effectively inhibit the proliferation and tumorigenicity of MB-CSCs and significantly synergistically enhance radiosensitivity in RV-treated MB-CSCs.
Authors: Aldo M Roccaro; Xavier Leleu; Antonio Sacco; Anne-Sophie Moreau; Evdoxia Hatjiharissi; Xiaoying Jia; Lian Xu; Bryan Ciccarelli; Christopher J Patterson; Hai T Ngo; Domenico Russo; Angelo Vacca; Franco Dammacco; Kenneth C Anderson; Irene M Ghobrial; Steven P Treon Journal: Clin Cancer Res Date: 2008-03-15 Impact factor: 12.531
Authors: Mary Jo Atten; Ernesto Godoy-Romero; Bashar M Attar; Thomas Milson; Matthew Zopel; Oksana Holian Journal: Invest New Drugs Date: 2005-03 Impact factor: 3.850
Authors: Felix Zeppernick; Rezvan Ahmadi; Benito Campos; Christine Dictus; Burkhard M Helmke; Natalia Becker; Peter Lichter; Andreas Unterberg; Bernhard Radlwimmer; Christel C Herold-Mende Journal: Clin Cancer Res Date: 2008-01-01 Impact factor: 12.531
Authors: Dagmar Beier; Jörg Wischhusen; Wolfgang Dietmaier; Peter Hau; Martin Proescholdt; Alexander Brawanski; Ulrich Bogdahn; Christoph P Beier Journal: Brain Pathol Date: 2008-03-26 Impact factor: 6.508
Authors: Paul A Clark; Saswati Bhattacharya; Ardem Elmayan; Soesiawati R Darjatmoko; Bradley A Thuro; Michael B Yan; Paul R van Ginkel; Arthur S Polans; John S Kuo Journal: J Neurosurg Date: 2016-07-15 Impact factor: 5.115
Authors: Anwar Zaiter; Zahraa F Audi; Fatima Shawraba; Zahraa Saker; Hisham F Bahmad; Rami H Nabha; Hayat Harati; Sanaa M Nabha Journal: Mol Biol Rep Date: 2022-06-18 Impact factor: 2.316
Authors: Sharmila Shankar; Dara Nall; Su-Ni Tang; Daniel Meeker; Jenna Passarini; Jay Sharma; Rakesh K Srivastava Journal: PLoS One Date: 2011-01-31 Impact factor: 3.240